Fallopian Tube Carcinosarcoma
Associated Genetic Biomarkers
NCI Definition: A carcinosarcoma that arises from the fallopian tube. It usually affects postmenopausal women and presents with abdominal pain, abdominal distension or genital bleeding. The prognosis is usually poor. 
There are 9 clinical trials for fallopian tube carcinosarcoma, of which 7 are open and 2 are completed or closed. Of the trials that contain fallopian tube carcinosarcoma as an inclusion criterion, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 4 are phase 2 (3 open).
ATM, ATR, and BARD1 are the most frequent gene inclusion criteria for fallopian tube carcinosarcoma clinical trials .
Cisplatin, nivolumab, and pembrolizumab are the most common interventions in fallopian tube carcinosarcoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.